Monte Rosa Therapeutics, Inc. Income Statement
GLUE / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| SG&A Expense | $35.2M | $32.0M | $27.3M | $15.7M | $4.0M |
| R&D Expense | $121.6M | $111.3M | $85.1M | $57.2M | $24.0M |
| Operating Income | -$81.1M | -$143.3M | -$112.4M | -$72.9M | -$28.0M |
| Income Tax | $2.6M | $338.0K | $0 | - | - |
| Net Income | -$72.7M | -$135.4M | -$108.5M | -$74.0M | -$35.9M |
| Shares Outstanding | 73.9M | 51.4M | 47.2M | 25.0M | 1.5M |